HeartBeam, a medical technology company trading on NASDAQ under the symbol BEAT, announced it is commencing an underwritten public offering of shares of its common stock or common stock equivalents. The company stated that the final size and terms of the offering are subject to market conditions. According to the announcement, HeartBeam intends to use the net proceeds from this offering to advance several key initiatives central to its mission of transforming cardiac care.
The primary allocation of funds will support the commercialization of the company’s FDA-cleared 12-lead synthesized ECG system. This technology represents a significant innovation, as it is designed to be the first cable-free device capable of collecting ECG signals in three dimensions from non-coplanar directions and synthesizing them into a standard 12-lead ECG. The platform is intended for portable use, allowing for heart monitoring outside traditional medical facilities. The company’s 12-lead ECG synthesis software received FDA clearance in December 2025, following clearance for arrhythmia assessment in December 2024.
Additional proceeds are earmarked for the further development of an extended-wear patch and heart attack detection initiatives. A portion of the funds will also be dedicated to enhancing the company’s artificial intelligence capabilities, which are integral to analyzing the cardiac data collected by its devices. The remaining proceeds will support general working capital and corporate purposes. Titan Partners, a division of American Capital Partners, is acting as the sole bookrunner for the offering. The company holds over 20 issued patents related to its core technology.
The initiative underscores a strategic push to bring advanced, portable cardiac diagnostics to a broader patient population. By enabling physicians to identify cardiac health trends and acute conditions remotely, HeartBeam’s technology aims to direct patients to appropriate care more efficiently. The success of this funding effort could accelerate the availability of these tools, potentially impacting how heart conditions are monitored and managed in everyday settings. For more information, the company maintains a newsroom at https://ibn.fm/BEAT.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is HeartBeam Announces Public Offering to Fund Cardiac Technology Commercialization and AI Development.